Related ArticlesAdalimumab in psoriatic arthritis : a viewpoint by eric ruderman.
Drugs. 2006;66(11):1497-9
Authors: Ruderman E
PMID: 16906785 [PubMed - in process]
]]>
Adalimumab in psoriatic arthritis: a viewpoint by andrea doria and paolo sfriso.
Drugs. 2006;66(11):1497-9
Authors: Doria A, Sfriso P
PMID: 16906784 [PubMed - in process]
]]>
Adalimumab in psoriatic arthritis : a viewpoint by philip mease.
Drugs. 2006;66(11):1497-9
Authors: Mease P
PMID: 16906783 [PubMed - in process]
]]>
Adalimumab : in psoriatic arthritis.
Drugs. 2006;66(11):1487-96
Authors: Simpson D, Scott LJ
black triangle Adalimumab, a fully human monoclonal antibody, is a tumour necrosis factor antagonist that has been investigated for efficacy in psoriatic arthritis, based on well-established use of the drug in rheumatoid arthritis.black triangle In well-controlled Phase III trials, adalimumab (40 mg administered subcutaneously every other week) has shown efficacy in adult patients with psoriatic arthritis who had an inadequate response to previous treatment with NSAIDs (24-week ADEPT trial; n = 313) or disease-modifying antirheumatic drugs (12-week study; n = 100).black triangle In these trials, adalimumab recipients experienced a significantly greater improvement in arthritis response (p /=10% )Most frequently reportedInjection-site reactions, upper respiratory tract infection, headache, rash and sinusitis.
PMID: 16906782 [PubMed - in process]
]]>
Psoriatic arthritis and rheumatoid arthritis: findings in contrast-enhanced MRI.
AJR Am J Roentgenol. 2006 Aug;187(2):351-7
Authors: Schoellnast H, Deutschmann HA, Hermann J, Schaffler GJ, Reittner P, Kammerhuber F, Szolar DH, Preidler KW
OBJECTIVE: Our objective was to define typical MRI findings of the wrist and the hand in patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA). MATERIALS AND METHODS: Eighteen PsA and 21 RA patients with arthralgia of the wrist or hand joints underwent gadolinium-enhanced MRI of the wrist and hand. Two experienced radiologists interpreted abnormalities in consensus with respect to periarticular soft-tissue swelling, synovitis with or without effusion, periostitis, bone edema, bone erosions, bone cysts, and tenosynovitis. The distribution of the abnormalities also was evaluated. RESULTS: Erosions were statistically more frequent in patients with RA (p 0.05). The radiocarpal joint, the midcarpal joints, the carpometacarpal joints, and the metacarpophalangeal joints were significantly affected more frequently in patients with RA than in patients with PsA (p
PMID: 16861537 [PubMed - indexed for MEDLINE]
]]>
Purpura and serum mixed cryoglobulinemia in psoriatic arthritis.
Rheumatol Int. 2006 Aug 10;
Authors: Palazzi C, D’Amico E, Pennese E, Petricca A, Olivieri I
We here firstly describe the case of a psoriatic arthritis associated with cutaneous purpura and lower limbs weakness. The presence of type III mixed cryoglobulinemia in serum was the only possible detected cause. Discrepancies with the hepatitis C virus-related mixed cryoglobulinemia picture are discussed.
PMID: 16900374 [PubMed - as supplied by publisher]
]]>
Related ArticlesPurpura and serum mixed cryoglobulinemia in psoriatic arthritis.
Rheumatol Int. 2006 Aug 10;
Authors: Palazzi C, D’Amico E, Pennese E, Petricca A, Olivieri I
We here firstly describe the case of a psoriatic arthritis associated with cutaneous purpura and lower limbs weakness. The presence of type III mixed cryoglobulinemia in serum was the only possible detected cause. Discrepancies with the hepatitis C virus-related mixed cryoglobulinemia picture are discussed.
PMID: 16900374 [PubMed - as supplied by publisher]
]]>
Related ArticlesPPAR-gamma gene polymorphisms and psoriatic arthritis.
J Rheumatol. 2006 Aug;33(8):1631-3
Authors: Butt C, Gladman D, Rahman P
OBJECTIVE: Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation has been shown to play a role in suppressing angiogenesis and inflammation, both important pathological features of psoriatic arthritis (PsA). Given the potential physiological role for PPAR-gamma in PsA, we examined known coding polymorphisms in the PPAR-gamma gene in a Caucasian population. METHODS: PsA was diagnosed as an inflammatory arthritis in patients with psoriasis, in the absence of other etiologies for inflammatory arthritis. Control subjects were ascertained from the same population and were all Caucasian. DNA samples were genotyped for 4 PPAR-gamma variants by time-of-flight mass spectrometry using the Sequenom platform. All 4 single-nucleotide polymorphisms (SNP) were previously-reported coding variations, 3 of which caused an amino acid change: Pro12Ala (rs1801282), Pro40Ala (rs1805192), and Pro115Gln (rs1800571); the fourth SNP, C161T (rs3856806), was synonymous. All primers were designed using Sequenom SpectroDesigner software, and scanned using a mass spectrometry workstation. RESULTS: Of the 4 SNP examined, Pro40Ala and Pro115Gln were found to be nonpolymorphic in our population. Minor allele frequency for patients with PsA and controls for Pro12Ala (G) were 9.0% vs 13.8% (p = 0.017) and for C161T (T) 10.7% vs 12.0% (p = 0.56), respectively. All genotypes satisfied Hardy-Weinberg equilibrium. CONCLUSION: An association between PsA and a known coding SNP of the PPAR-gamma gene was observed in our Caucasian population. Further studies are now warranted for validation of our findings in an independent cohort.
PMID: 16783862 [PubMed - in process]
]]>
Related ArticlesEstimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
Rheumatology (Oxford). 2006 Aug;45(8):1029-38
Authors: Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, Reynolds A, Emery P
OBJECTIVES: Tumour necrosis factor (TNF) has been shown to improve the outcomes in patients with psoriatic arthritis (PsA). We estimate the long-term impact on health status of prescribing the TNF antagonist etanercept, and evaluate the cost-effectiveness in a health economic model. METHODS: The relationship between disability (Health Assessment Questionnaire) and health state utility was explored to estimate the quality-adjusted life years (QALYs) gained from the TNF antagonist etanercept. A model was then used to compare sequences of treatments for PsA after failure of two conventional disease modifying anti-rheumatic drugs (DMARDs). One arm commences on etanercept therapy and this is compared with a strategy commencing with combination therapy of methotrexate and ciclosporin and another commencing with leflunomide. Individual patient data from Phase III etanercept trials is used to populate the model supported by published evidence from extensive literature searches. By incorporating a life table specific for a PsA population, and using a number of evidence- and expert opinion-based assumptions for disease progression, the model was extended beyond the trial duration to a 10-yr time horizon. Cost offsets were produced by avoiding surgery through delayed progression; drug and monitoring costs were also modelled. RESULTS: Over the 10 yrs, modelled etanercept treatment gave 0.82 more QALYs when compared with combination therapy with methotrexate and ciclosporin, and 0.65 more QALYs in comparison with leflunomide. This equates to a central estimate for the cost per QALY of pound28 189 and pound28 189 for ciclosporin and leflunomide, respectively. Sensitivity analyses demonstrated this could vary by as much as +/-28%. CONCLUSIONS: With limited data currently available, the potential cost-effectiveness of etanercept in DMARD failures for adults with PsA appears encouraging. The result for other TNF antagonists will depend on how their relative efficacy and drug price compares with etanercept. A number of limitations are described and priorities for further research suggested.
PMID: 16782734 [PubMed - in process]
]]>
High Prevalence of Thyroid Autoimmunity and Hypothyroidism in Patients with Psoriatic Arthritis.
J Rheumatol. 2006 Aug 1;
Authors: Antonelli A, Sedie AD, Fallahi P, Ferrari SM, Maccheroni M, Ferrannini E, Bombardieri S, Riente L
OBJECTIVE: To evaluate the prevalence of thyroid disorders in a group of patients with psoriatic arthritis (PsA). METHODS: A complete thyroid investigation was carried out in 80 patients with PsA, in gender- and age-matched subjects (1:5) drawn from the general population (controls), and in 112 patients with rheumatoid arthrtitis (RA) with similar iodine intake. RESULTS: Anti-thyroid peroxidase antibodies (AbTPO), a hypoechoic thyroid, and subclinical hypothyroidism were significantly more frequent in women with PsA than in control women, and their frequency was similar to that in patients with RA (positive AbTPO titer 28%, 12%, and 31%; hypoechoic thyroid 31%, 16%, and 36%; subclinical hypothyroidism 25%, 8%, and 12%, respectively). Among men, positive AbTPO titers and a hypoechoic thyroid were found more frequently in the patients with PsA and RA than in controls (positive AbTPO titer 14%, 5%, and 2%; hypoechoic thyroid 16%, 10%, and 3%, respectively). All patients with PsA with subclinical hypothyroidism had polyarticular involvement (p
PMID: 16881097 [PubMed - as supplied by publisher]
]]>